IFN-γ–related mRNA profile predicts clinical response to PD-1 blockadeMark Ayers, Terrill K. McClanahan, Jared Lunceford et al.|Journal of Clinical Investigation|2017Cited by 3.9k
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapyRăzvan Cristescu, David R. Kaufman, Jennifer H. Yearley et al.|Science|2018Cited by 2.3k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion CohortLaura Q.M. Chow, Tanguy Y. Seiwert, Robert I. Haddad et al.|Journal of Clinical Oncology|2016Cited by 859
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II StudyJoshua Bauml, Robert I. Haddad, Tanguy Y. Seiwert et al.|Journal of Clinical Oncology|2017Cited by 653
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012Ranee Mehra, Robert I. Haddad, Tanguy Y. Seiwert et al.|British Journal of Cancer|2018Cited by 457